ABSTRACT: Introduction: Recent studies have provided evidence that patients with myotonic dystrophy (DM) are at excess risk of cancer. However, inconsistencies regarding affected anatomic sites persist. Methods: We performed a meta-analysis of cancer risk in DM, searching among studies published between January 1, 1990 and December 31, 2016. Eligible studies were full reports of DM cohorts with site-specific risks. Results: The analysis included 5 studies, comprising 2,779 patients. Risk estimates for cancers of the endometrium and cutaneous melanoma were reported in all studies. The pooled standardized incidence ratio (pSIRs) for endometrial cancer was 7.48 (95% confidence interval [CI] 4.72-11.8) and for cutaneous melanoma was 2.45 (95% CI 1.31-4.58). Among cancers reported in 4 of 5 studies, elevated risks were observed for thyroid (pSIR = 8.52, 95% CI 3.62-20.1), ovarian (pSIR = 5.56, 95% CI 2.99-10.3), testicular (pSIR = 5.95, 95% CI 2.34-15.1), and colorectal (pSIR = 2.2, 95% CI 1.39-3.49) cancers. Discussion: Our data refine the DM cancer phenotype, which may guide patient clinical management and inform plans for molecular investigations to understand DMrelated carcinogenesis.
1
The disease is caused by a trinucleotide repeat expansion in the dystrophia myotonica-protein kinase (DMPK) gene in DM type 1 (DM1), [2] [3] [4] or a tetranucleotide repeat expansion in the zinc finger 9 (ZNF9) gene in DM type 2 (DM2). 5 The size of the nucleotide repeat expansion in DM1, but not DM2, is modestly correlated with disease severity and age at onset; congenital DM is the most severe form of the disease. 6 The phenotypic complexity of this disease may result from splicing dysregulation in the pre-mRNA of multiple genes. [7] [8] [9] Case reports and small case series have suggested that cancer may be part of the DM clinical phenotype. 10 Recently, several epidemiologic studies provided quantitative support for this notion. [11] [12] [13] [14] [15] However, there are interstudy inconsistencies regarding the specific sites of increased cancer involvement. It is possible that smaller studies were underpowered to detect rare cancerssuch as those of the brain or ovary-detected in larger DM studies. A recent study of 1,119 DM patients from Sweden showed that DM patients are at 5-fold higher risk of brain cancer when compared with the general population. 16 A precise listing of DM-related cancers is important for patient clinical management, as they represent the third leading cause of death in those patients. [17] [18] [19] In addition, this knowledge may guide the planning for molecular studies aiming at understanding DM-related carcinogenesis. Herein we used meta-analysis tools to pool cancer site-specific risk estimates across 5 relevant published studies.
METHODS
Data Sources and Study Selection. We searched 3 different databases (Medline, The Cochrane Library, Embase) for the terms "myotonic dystrophy," "Steinert's disease," "cancer," "malignancy," "neoplasm," "tumor," "carcinoma," "sarcoma," "lymphoma," and "risk," from the period January 1, 1990 through December 31, 2016. Reference lists from the reports retrieved were examined and additional references included if pertinent. No language restriction was applied. This initial search was completed by an experienced librarian, and abstracts were screened by J.I.E. Selected full texts were reviewed by J.I.E. and S.M.G. The inclusion criteria of selected studies for this analysis were: (1) full reports; (2) DM cohorts (independent of disease subtype); and (3) reported sitespecific cancers.
Data Extraction and Synthesis. We used a standardized abstraction form to extract the following: first author; year of publication; country; number of DM patients; age at DM and at cancer diagnosis; basis for DM diagnosis; source of cancer ascertainment; and relative risks (RRs) or standardized incidence ratios (SIRs), with corresponding 95% confidence intervals (CIs) for cancer risk for all organs combined, when available, and for all available cancer-site specific estimates. We used a 2-stage approach for data extraction to ensure accuracy; the first extraction was carried out by J.I.E. and then information was checked by S.M.G. Disagreements were resolved by consensus discussion.
Statistical Analysis. Study-specific SIRs with 95% CIs for all cancers combined and for specific cancer sites were aggregated using random effect models when significant heterogeneity was detected; otherwise, fixed effect models were used. Organ-specific SIRs were combined only if at least 3 studies reported estimates for that type of cancer. Unreported 95% CIs were calculated using the Poisson distribution based on observed and expected numbers of cancer. We assessed the heterogeneity between cohorts using the Cochran Q test and I 2 statistic. Heterogeneity was considered significant when P < 0.05 for the Cochran Q test or I 2 > 50%. In rare situations in which heterogeneity was caused by a particular study, we reported pooled SIR (pSIR) with and without the study of concern. We stratified our analyses by continent (USA vs. Europe) and by type of study (clinic-based vs. populationbased) to test the effect of these factors on result heterogeneity.
All analyses were performed using STATA/SE version 14 (StataCorp LP, College Station, Texas)
RESULTS
A total of 35 studies were screened for inclusion; 22 were judged irrelevant, leaving 13 studies for eligibility assessment. We excluded studies with selfreported cancers or prevalence estimates (these studies mainly focused on identifying risk factors for tumor development), those with no comparison group for cancer risk calculations (cancer absolute risk studies), and 1 study assessing risk in DM relatives. Figure 1 describes the study selection scheme.
Our final pool included 5 cohort studies (2 clinicbased and 3 population-based). The largest study comprised 1,658 DM patients identified primarily from inpatient hospital records in Sweden and Denmark, and provided the initial evidence supporting an excess cancer risk of the following cancers: endometrial (SIR = 7.6, 95% CI 4.0-13.2); ovarian Possible excesses of thyroid (SIR = 7.1, P = 0.01), ocular melanoma (SIR = 12.0, P = 0.01), and pancreatic cancer (SIR = 3.2, P = 0.05) were also reported, none of which reached statistical significance after adjusting for multiple comparisons. 11 Win et al. (307 DM patients) replicated the elevated risks of thyroid and eye cancer, and suggested a possible testicular cancer risk (SIR = 5.1, P = 0.06).
12 Two subsequent smaller studies, from France (n = 109) and the United States (n = 281), replicated the endometrial cancer finding (both studies), and that of testicular cancer (only the USA study). 13, 14 The study by Abbott et al. also suggested that DM patients may be at excess risk of non-Hodgkin lymphoma (SIR = 4.25, 95% CI 1.16-12.43), 14 whereas Mohamed et al. suggested an association with lung cancer (relative risk [RR] = 6, 95% CI 1.2-17.7). 13 Most recently, a study from northern Spain (424 patients with genetically confirmed DM1) replicated the results of the original study, except that the positive colorectal cancer association (SIR = 2.06, 95% CI 0.94-3.92) did not quite achieve statistical significance, and the thyroid cancer association (SIR = 23.33; 95% CI 9.38-48.08) was stronger.
15 Table 1 summarizes the design and patients' characteristics for each of the selected studies.
Pooled Cancer Risk Estimates. Risk estimates for only 2 cancer sites (endometrium and cutaneous melanoma) were reported in all 5 studies. Pooled risk estimates showed that DM patients were at significantly increased risk of both cancers (P < 0.001 for endometrium, P = 0.005 for cutaneous melanoma) ( Fig. 2A and B) .
For cancers reported by 4 studies, the highest risk estimate was for thyroid cancer (P < 0.001); however, significant interstudy heterogeneity was observed (I 2 = 60%, P = 0.06). Results from a random effects model attenuated the effect sizes, but risks remained high and statistically significant (pSIR = 8.52, P < 0.001). Other cancers occurring excessively included ovary, testis (P < 0.001), and colon/rectum (P = 0.001) (Fig. 3A-D) . Table S1 (refer to Supplementary Material available online) summarizes pooled SIRs by cancer anatomic site for cancers that were reported in at least 3 studies, along with measures of heterogeneity. For these, our analysis suggested elevated risks for brain cancer and non-Hodgkin lymphoma. Pooled results for breast, prostate, lung, kidney, and leukemia should be interpreted with caution, as wide confidence intervals were observed, indicating imprecise point estimates.
Sensitivity Analyses and Publication Bias. We performed several stratified meta-analyses for results with significant heterogeneity (risk estimates for cancers of the thyroid, lung, and prostate). We stratified by geographic region (USA vs. Europe) and by type of study (clinic-based vs. population-based).
For thyroid cancer, the heterogeneity was due entirely to the European studies (see Fig. S1A online). In fact, excluding the study by Fernández-Torrón et al. diminished the I 2 to zero. Results after exclusion still supported an excess risk of thyroid cancer in DM patients (pSIR = 5.56, 95% CI 2.82-10.95). For prostate cancer, studies from the USA showed higher SIRs than studies from Europe, and heterogeneity disappeared with stratified analysis by continent subgroup (see Fig. S1B online) ; however, the results from stratified analyses remained inconsistent. In the case of lung cancer, the heterogeneity remained in the clinic-based subgroup, with no heterogeneity in the population-based subgroup (see Fig. S1C online) , but results are inconclusive.
Funnel plots for endometrial cancer and cutaneous melanoma are included (see Fig. S2 online) . Yet, reliable assessment of publication bias was not possible because of the small number of studies included in this meta-analysis. 
DISCUSSION
In this meta-analysis we sought to clarify which specific cancers may comprise components of the DM phenotype, to inform both patient management and translational research aimed at understanding DMassociated carcinogenesis. This association is relatively new, and the relatively small sample sizes in 4 of the 5 published studies to date made it difficult to infer the answer to the phenotype question. Pooled estimates using 2,779 patients from 5 DM cohorts (3 European from 4 different countries, and 2 from the USA) demonstrated significant, consistent excesses of cancers of the thyroid, endometrium, ovary, cutaneous melanoma, colon/rectum, and testis (at least 4 cohorts included in the analysis), plus possibly brain cancer, and non-Hodgkin lymphoma (3 cohorts included) .
The largest-to-date epidemiologic investigation of cancer risk in DM showed a statistically significant excess risk for cancers of the endometrium, ovary, brain, and colon. 11 Those 4 cancers present a pattern reminiscent of that seen in Lynch syndrome, 18 raising the possibility that an abnormality of DNA mismatch repair may underlie their occurrence. Several subsequent smaller studies validated some, but not all, of the original findings, and suggested the possibility of other affected organs. [12] [13] [14] [15] Inconsistencies between studies regarding specific cancer associations may be due to selection bias in clinicbased studies, diagnosis misclassification in registry studies, or differences in patient characteristics, such as DM severity or DM subtype. A cross-sectional analysis of a large DM study including 781 DM1 and 130 DM2 patients showed that tumor risk is higher in DM1 than DM2, and suggested different tumor profiles in the 2 subtypes. 20 Studies included in this meta-analysis were expected to be skewed toward DM1 patients as DM1 is more common (2 studies included DM1 only, 2 studies included all DM patients [unknown subtype], and 1 study included a subset of known DM2 patients). The study by Win et al. showed that DM2 patients (n = 86) are at excess risk of prostate cancer (SIR = 3.36, P = 0.008) and possibly thyroid cancer (SIR = 5.7, P = 0.05).
12 Cancer risk in patients with DM2 is still undefined and needs to be studied in a large, well-designed study.
It is also possible that some of the findings were confounded by unmeasured behavioral risk factors, such as smoking and lung cancer, exogenous hormones, and endometrial or ovarian cancer, etc. Several studies looking at the effect of known risk factors on DM cancer risk, all sites combined, indicated no association with smoking, alcohol, or body mass index. [20] [21] [22] However, a recent analysis of skin cancer risk factors in DM patients showed increased risks in subjects reporting a blistering sunburn after sun exposure (odds ratio = 4.28, 95% CI 0.91-19.95, P = 0.06). 23 Large, well-designed studies of genetically confirmed DM patients with comprehensive risk factor information are needed to investigate the possible interactions between genetically predisposed DM patients and environmental exposures in DMrelated carcinogenesis.
The molecular mechanism underlying DM carcinogenesis is still unclear. Perhaps the most appealing hypothesis is that DM alternative splicing abnormality may alter the expression of oncogene or tumor suppressor genes. As a possible example, Fernández-Torrón and colleagues described differential transcription/expression of several cancer-associated genes (PDK4, DAPK1, CASP5, and PLA2G7) in DM1 patients, and observed that the 200c/141microRNA tumor suppressor family was down-regulated in female DM1 patients. 15 It was also suggested that cancer in DM is part of a generalized premature aging phenotype, 24 a hypothesis yet to be tested. Translational research efforts aimed at elucidating the molecular biologic basis for recently recognized DM-related carcinogenesis represent a fertile domain for identifying novel cancer pathogenesis pathways.
There are limitations to the present study. Metaanalysis is a powerful statistical approach to synthesizing evidence from pooling results across studies and identifying sources of interstudy heterogeneity; nonetheless, it is limited by its inability to answer new questions or to overcome deficiencies in the published literature. In addition, it is prone to the effect of publication bias. 25 The small number of included studies limited our ability to effectively study such bias. Our study is also limited by the absence of site-specific cancer risk estimates for all anatomic sites in all published studies, which may result in overestimating the risks, as unpublished associations tend to be null. Herein we focused explicitly on cancers reported in at least 3 of the 5 existing studies in order to minimize this concern.
In conclusion, this meta-analysis has confirmed that DM patients are at high risk of specific malignancies, including cancers of the thyroid, endometrium, ovary, cutaneous melanoma, colon/rectum, and testis, and possibly brain cancer and non-Hodgkin lymphoma. A larger, well-designed study of genetically confirmed DM patients is needed to confirm these findings. Our analysis has reasonably designated the aforementioned cancers as those most clearly associated with DM, comprising the best target for etiologically oriented laboratory research efforts.
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